These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 33255393)

  • 21. The Impella device for acute mechanical circulatory support in patients in cardiogenic shock.
    Lemaire A; Anderson MB; Lee LY; Scholz P; Prendergast T; Goodman A; Lozano AM; Spotnitz A; Batsides G
    Ann Thorac Surg; 2014 Jan; 97(1):133-8. PubMed ID: 24090575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Secular Trend in the Use and Implementation of Impella in High-Risk Percutaneous Coronary Intervention and Cardiogenic Shock: A Real-World Experience.
    Hritani AW; Wani AS; Olet S; Lauterbach CJ; Allaqaband SQ; Bajwa T; Jan MF
    J Invasive Cardiol; 2019 Sep; 31(9):E265-E270. PubMed ID: 31478893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiogenic Shock Complicating Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention Supported by Impella: Implications of Advanced Age and Refractory Shock on Outcomes.
    Boshara A; Patel A; Alasaad M; Dutcheshen KJ; LaLonde TA; Schreiber TL; Mehta RH; Kaki A; Rosman HS
    Crit Care Explor; 2021 Jun; 3(6):e0447. PubMed ID: 34136823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management and outcome of patients supported with Impella 5.0 for refractory cardiogenic shock.
    Gaudard P; Mourad M; Eliet J; Zeroual N; Culas G; Rouvière P; Albat B; Colson P
    Crit Care; 2015 Oct; 19():363. PubMed ID: 26453047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of Mortality and Outcomes of Acute Severe Cardiogenic Shock Treated with the Impella Device.
    Rohm CL; Gadidov B; Leitson M; Ray HE; Prasad R
    Am J Cardiol; 2019 Aug; 124(4):499-504. PubMed ID: 31262498
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Impella 2.5 and 5.0 devices for ST-elevation myocardial infarction patients presenting with severe and profound cardiogenic shock: the Academic Medical Center intensive care unit experience.
    Engström AE; Cocchieri R; Driessen AH; Sjauw KD; Vis MM; Baan J; de Jong M; Lagrand WK; van der Sloot JA; Tijssen JG; de Winter RJ; de Mol BA; Piek JJ; Henriques JP
    Crit Care Med; 2011 Sep; 39(9):2072-9. PubMed ID: 21602670
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Propensity score-based analysis of 30-day survival in cardiogenic shock patients supported with different microaxial left ventricular assist devices.
    Nersesian G; Potapov EV; Nelki V; Stein J; Starck C; Falk V; Schoenrath F; Krackhardt F; Tschöpe C; Spillmann F
    J Card Surg; 2021 Nov; 36(11):4141-4152. PubMed ID: 34460968
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Percutaneous Ventricular Assist Devices: A Health Technology Assessment.
    Health Quality Ontario
    Ont Health Technol Assess Ser; 2017; 17(2):1-97. PubMed ID: 28232854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes of Hemodynamic Support With Impella for Acute Myocardial Infarction Complicated by Cardiogenic Shock at a Rural Community Hospital Without On-Site Surgical Back-up.
    Wilkins CE; Herrera TL; Nagahiro MK; Weathers LB; Girotra SV; Sandhu F
    J Invasive Cardiol; 2019 Feb; 31(2):E23-E29. PubMed ID: 30700627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Percutaneous biventricular Impella support in therapy-refractory cardiogenic shock.
    Chiu CY; Hättasch R; Praeger D; Knebel F; Stangl K; Ramirez ID; Dreger H
    Heart Lung; 2018; 47(3):250-252. PubMed ID: 29628145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanical circulatory support with the Impella® LP5.0 pump and an intra-aortic balloon pump for cardiogenic shock in acute myocardial infarction: The IMPELLA-STIC randomized study.
    Bochaton T; Huot L; Elbaz M; Delmas C; Aissaoui N; Farhat F; Mewton N; Bonnefoy E;
    Arch Cardiovasc Dis; 2020 Apr; 113(4):237-243. PubMed ID: 31740272
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rationale and design of DanGer shock: Danish-German cardiogenic shock trial.
    Udesen NJ; Møller JE; Lindholm MG; Eiskjær H; Schäfer A; Werner N; Holmvang L; Terkelsen CJ; Jensen LO; Junker A; Schmidt H; Wachtell K; Thiele H; Engstrøm T; Hassager C;
    Am Heart J; 2019 Aug; 214():60-68. PubMed ID: 31176289
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impella-Induced Incessant Ventricular Tachycardia.
    Kaki A; Subahi A; Shokr M; Ibrahim W; Yassin A; Hasan R; Alraies MC; Schreiber T
    Ochsner J; 2019; 19(3):248-251. PubMed ID: 31528136
    [No Abstract]   [Full Text] [Related]  

  • 34. Impella RP for Patients with Acute Right Ventricular Failure and Cardiogenic Shock: A Subanalysis from the IMP-IT Registry.
    Botti G; Gramegna M; Burzotta F; Masiero G; Briguori C; Trani C; Napodano M; Scandroglio AM; Montorfano M; Tarantini G; Chieffo A;
    J Pers Med; 2022 Sep; 12(9):. PubMed ID: 36143266
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cVAD registry for percutaneous temporary hemodynamic support: A prospective registry of Impella mechanical circulatory support use in high-risk PCI, cardiogenic shock, and decompensated heart failure.
    Vetrovec GW; Anderson M; Schreiber T; Popma J; Lombardi W; Maini B; Moller JE; Schäfer A; Dixon SR; Hall S; Ohman EM; Mindrescu C; Moses J; O'Neill W
    Am Heart J; 2018 May; 199():115-121. PubMed ID: 29754648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence and Outcomes of Acute Kidney Injury Requiring Renal Replacement Therapy in Patients on Percutaneous Mechanical Circulatory Support with Impella-CP for Cardiogenic Shock.
    Fahad F; Saad Shaukat MH; Yager N
    Cureus; 2020 Jan; 12(1):e6591. PubMed ID: 32051803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Switching to Impella 5.0 decreases need for transfusion in patients undergoing temporary mechanical circulatory support.
    Castro L; Zipfel S; Braunsteiner J; Schaefer A; Sill B; Söffker G; Kluge S; Lubos E; Rybczinski M; Grahn H; Schrage B; Becher PM; Barten MJ; Westermann D; Blankenberg S; Reichenspurner H; Bernhardt AM
    J Crit Care; 2020 Jun; 57():253-258. PubMed ID: 32423622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prolonged Impella 5.0/5.5 support within different pathways of care for cardiogenic shock: the experience of a referral center.
    Pieri M; Ortalda A; Altizio S; Bertoglio L; Nardelli P; Fominskiy E; Lapenna E; Ajello S; Scandroglio AM
    Front Cardiovasc Med; 2024; 11():1379199. PubMed ID: 39015682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concomitant implantation of Impella
    Pappalardo F; Schulte C; Pieri M; Schrage B; Contri R; Soeffker G; Greco T; Lembo R; Müllerleile K; Colombo A; Sydow K; De Bonis M; Wagner F; Reichenspurner H; Blankenberg S; Zangrillo A; Westermann D
    Eur J Heart Fail; 2017 Mar; 19(3):404-412. PubMed ID: 27709750
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The contemporary role of Impella in a comprehensive mechanical circulatory support program: a single institutional experience.
    Pieri M; Contri R; Winterton D; Montorfano M; Colombo A; Zangrillo A; De Bonis M; Pappalardo F
    BMC Cardiovasc Disord; 2015 Oct; 15():126. PubMed ID: 26466899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.